|
PELI1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
2.044300E-02 |
| Normal-vs-Stage3 |
6.06950001369455E-09 |
| Normal-vs-Stage4 |
3.94900000477705E-08 |
| Stage1-vs-Stage2 |
2.263800E-02 |
| Stage1-vs-Stage3 |
3.091400E-01 |
| Stage1-vs-Stage4 |
9.680800E-01 |
| Stage2-vs-Stage3 |
9.696200E-02 |
| Stage2-vs-Stage4 |
2.879900E-02 |
| Stage3-vs-Stage4 |
4.667200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
6.515600E-03 |
| Normal-vs-Asian |
4.13489999999683E-05 |
| Caucasian-vs-AfricanAmerican |
5.452400E-01 |
| Caucasian-vs-Asian |
4.654800E-01 |
| AfricanAmerican-vs-Asian |
3.612000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.94159976563935E-10 |
| Normal-vs-Female |
1.11022302462516E-16 |
| Male-vs-Female |
8.800200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62680979798324E-12 |
| Normal-vs-Age(41-60Yrs) |
1.68169922432071E-11 |
| Normal-vs-Age(61-80Yrs) |
4.78140000037541E-07 |
| Normal-vs-Age(81-100Yrs) |
1.523640E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.795600E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.631850E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.680800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.577810E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.464400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.663980E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.742800E-01 |
| Classical-VS-Follicular |
1.62447832963153E-12 |
| Classical-VS-Other |
3.868800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
2.69339994751761E-10 |
| Tall-VS-Other |
4.002400E-01 |
| Tall-VS-Normal |
3.51769946504987E-10 |
| Follicular-VS-Other |
1.360400E-01 |
| Follicular-VS-Normal |
9.147400E-01 |
| Other-VS-Normal |
1.402200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.00750030119468E-10 |
| Normal-vs-N1 |
5.62460078512572E-11 |
| N0-vs-N1 |
1.94242000000067E-05 |
|
|
